95 Sizing the Opportunity: Precision Therapies Based on our research, as technologies like CRISPR gene editing, sequencing, and artificial intelligence (AI) create precision therapies, the enterprise value of precision therapy companies should appreciate at a ~28% compound annual growth rate (CAGR)during the next seven years, from ~$820 billion in 2023 to ~$4 trillion by 2030. Precision Therapy Enterprise Value Should Appreciate 28% Annual Rate Through 2030 S Cell Therapies Gene Editing/Therapy RNA Therapeutics Antibodies Precision Small Molecules E PI A $5.0 R CAGR E $4.5 H 21% T N $4.0 O 11% I S I $3.5 C 16% E ns $3.0 PR io 46% l $2.5 il r T $2.0 $1.5 34% $1.0 $0.5 $0.0 2023 2030 Forecast Sources: ARK Investment Management LLC, 2024. This ARK analysis is based on a range of external sources, including S&P Capital IQ Data and Biomedtracker, which may be provided upon request. Forecasts are inherently limited and cannot be relied upon. For informational purposes only and should not be considered investment advice or a recommendation to buy, sell, or hold any particular security. Past performance is not indicative of future results.